Introduction: Galectin-3 has a wide range of effects on tumor development, including cell proliferation, apoptosis, cell adhesion, invasion, angiogenesis, and metastasis. Macrophages migration inhibitory factor is a pleiotropic inflammatory cytokines found in many cell processes and especially in cancer. It has been said to interact with many tumor cells. For these reasons, we aim to explain the relationship between Galectin-3 and MIF proteins in the serum of blood samples of prostate cancer patients on VEGF and IL-6 release in prostate cancer patients in this study.
Methods: Our study group consists of Healthy control, Bening prostatic hyperplasia, prostate cancer, operated prostate cancer and metastatic prostate cancer group (each group will consist of 20 people). Protein levels were then measured using the Eliza analyse in these collected blood.
Results: A statistical increase in VEGF, MIF, Galectin-3 and IL-6 levels was observed in patients with cancer benign prostatic hyperplasia, radical prostectomy and metastasis in the control group. In the cancer group, there was a statistically significant decrease in VEGF, MIF, Galectin-3 and IL-6 levels in patients with benign prostatic hyperplasia and radical prostectomy, while a statistically significant increase was observed in VEGF, MIF, Galectin-3 and IL-6 levels in the metastasis group. In patients with radical prostectomy, MIF and Galectin-3 levels decreased statistically, while VEGF and IL-6 levels increased statistically.
Conclusions: These markers may be a new marker in the diagnosis and monitoring of treatment of prostate patients. We think we should do more studies on this subject.